Is AOD-9604 Legal in Florida?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment derived from the C-terminus of human growth hormone, specifically residues 176 to 191. Researchers originally studied it as an anti-obesity compound because preclinical data suggested it stimulated lipolysis and inhibited lipogenesis without the insulin-resistance or IGF-1-elevating effects seen with full-length growth hormone. Pharmaxis Ltd conducted Phase II and Phase III trials for an oral AOD-9604 formulation in obese adults between 2004 and 2007, but the compound never achieved the weight-loss endpoints required for FDA approval.

The Clinical Trial History

The largest clinical work on AOD-9604 used oral dosing at 1 mg daily. A 24-week randomized, double-blind, placebo-controlled trial (N=300 obese adults) showed no statistically significant difference in body weight between AOD-9604 and placebo (P=0.23). [1] Because the molecule failed its primary endpoint, the developer chose not to pursue FDA approval for a drug application, leaving AOD-9604 in a peculiar position: studied in humans, never approved, and now repurposed by the compounding industry as an injectable weight-loss peptide at doses far higher than those tested in trials.

How It Differs From Approved Peptides

Some peptides used in compounding, such as sermorelin (GHRH 1-29), held or currently hold FDA approval in some formulation. Sermorelin was approved under NDA 020706 and has a clearer compounding lineage. AOD-9604 has no such anchor. That distinction matters enormously when parsing compounding law.

The Federal Legal Framework for AOD-9604

Understanding AOD-9604's legality in Florida requires starting at the federal layer, because federal law controls what compounding pharmacies across all 50 states may legally prepare. The Drug Quality and Security Act (DQSA) of 2013 established two separate categories of compounding pharmacy: 503A traditional pharmacies and 503B outsourcing facilities.

Section 503A: Traditional Compounding Pharmacies

A 503A pharmacy may compound a drug that is not commercially available, provided several conditions are met. [2] One of those conditions is that bulk drug substances used in compounding must either be components of an FDA-approved drug, or appear on the FDA's published "bulk drug substances" list, sometimes called the "503A bulks list." The FDA has been methodically reviewing substances nominated to that list since 2016.

AOD-9604 was nominated for inclusion. After scientific and regulatory review, the FDA placed it in Category 2, meaning the agency determined there was insufficient evidence of clinical usefulness to support its inclusion on the 503A bulk list. A Federal Register notice from the FDA's Pharmacy Compounding Advisory Committee process confirmed AOD-9604's Category 2 designation, effectively meaning a 503A pharmacy may not compound it as a bulk substance without an existing FDA-approved drug to reference.

This is a meaningful restriction. It does not make possession of AOD-9604 a criminal offense for a patient. It does make it unlawful for a licensed 503A pharmacy to compound and dispense AOD-9604 without an approved drug component basis.

Section 503B: Outsourcing Facilities

503B outsourcing facilities operate under tighter FDA oversight, more like drug manufacturers. They may compound drugs without patient-specific prescriptions for distribution to health systems, but they are restricted to compounding copies or alternatives to FDA-approved drugs. Because no FDA-approved drug contains AOD-9604, a 503B facility has no legal basis to compound it. [3]

Investigational New Drug (IND) Pathway

The one federally sanctioned route for human use of unapproved substances like AOD-9604 is through an FDA-authorized Investigational New Drug application. Under 21 CFR Part 312, a physician or institution may file a single-patient expanded-access IND to use an investigational compound outside of a formal clinical trial. This pathway exists but is administratively demanding and rarely used for routine clinical weight-loss therapy.

Florida State Law and AOD-9604

Florida does not have a state statute that specifically names AOD-9604 and bans or permits it. Florida's legal framework for compounding builds on federal law rather than replacing it.

Florida Pharmacy Act, Chapter 465

The Florida Pharmacy Act (Chapter 465, Florida Statutes) governs the practice of pharmacy in the state, including compounding. Florida Statute 465.0276 specifically addresses compounding of drug products and requires that any compounded drug comply with applicable federal law, including DQSA requirements. A Florida-licensed 503A pharmacy that compounds AOD-9604 from bulk without a federally permissible basis is therefore also in potential violation of state pharmacy law, because state law references federal compliance as a condition of lawful operation.

Florida Board of Pharmacy Oversight

The Florida Board of Pharmacy operates under the Department of Health and has authority to investigate and discipline pharmacies and pharmacists who violate compounding rules. The Board can revoke a pharmacy permit, impose fines, and refer cases to federal regulators. The Board has not issued a specific advisory opinion on AOD-9604 as of this article's review date, but its statutory authority to enforce federal compliance standards applies regardless.

Florida Medical Practice Act and Prescriber Liability

Under Florida Statute 458.331, a physician may be disciplined for prescribing a drug or substance without a legitimate medical purpose or without an adequate patient evaluation. A prescription for AOD-9604 written to a patient the physician has never evaluated, or written without a documented clinical rationale, creates prescriber liability even if the substance itself is not a controlled drug. [4]

Florida telehealth law (Florida Statute 456.47) permits prescribing via telehealth if the prescriber establishes a patient-provider relationship, conducts an appropriate evaluation, and documents informed consent. A Florida-licensed telehealth provider writing an AOD-9604 prescription meets the state's prescriber requirements on the physician side. The remaining constraint is on the pharmacy dispensing it.

The Gray Area Explained Plainly

The phrase "gray area" gets used loosely about peptides. For AOD-9604 in Florida, the gray area is real but narrow.

The following framework describes the actual legal positions a Florida patient, prescriber, and pharmacy each occupy:

The patient who receives and self-administers AOD-9604 faces no federal criminal penalty. AOD-9604 is not a controlled substance under the Controlled Substances Act (21 USC 812), and personal possession is not prosecuted. State law similarly creates no possession offense for this molecule.

The prescribing physician who writes a valid patient-specific prescription, documents a clinical evaluation, and sends the script to a pharmacy is acting within prescriber authority. The prescriber does not compound the drug. Liability arises if the prescriber bypasses a real evaluation or makes false representations about intended use.

The pharmacy occupies the narrowest legal position. A 503A pharmacy compounding AOD-9604 from bulk as a finished injectable product is operating outside the FDA's current 503A bulk list. FDA warning letters to compounding pharmacies have cited exactly this type of violation for other peptides. The FDA issued widespread warning letters to compounding pharmacies in 2023 for offering BPC-157, TB-500, and similar peptides not on the 503A bulk list, signaling active enforcement in this category.

Some pharmacies argue that AOD-9604 can be compounded as a component of an approved drug because it shares sequence homology with fragments of human growth hormone. This argument has not been validated in any FDA guidance or court ruling as of 2025. Pharmacies making this argument are taking a legal risk that patients should understand before relying on them.

How Enforcement Actually Works

Enforcement of compounding law in Florida follows a layered structure. The FDA's Office of Pharmaceutical Quality conducts inspections of compounding facilities. If a facility is found to be compounding AOD-9604 without a compliant basis, the FDA may issue a Form 483 inspection observation, followed by a Warning Letter, followed in serious cases by an injunction or seizure. The FDA does not typically investigate or charge individual patients.

The Florida Department of Health and the Board of Pharmacy may receive referrals from the FDA or act on complaints. A pharmacy that loses its state permit cannot dispense anything, so the risk to the pharmacy is existential. A physician who receives a Board complaint faces a formal investigation, potential fines, and in severe cases, license suspension.

No Florida case law as of the article's review date has specifically adjudicated the legality of AOD-9604 compounding. The legal risk for the pharmacy is real and documented by parallel FDA enforcement actions against other unapproved peptides.

How to Get AOD-9604 Legally in Florida

Given the framework above, here is what a compliant pathway looks like in practice.

Step 1: Establish Care With a Licensed Florida Physician

Whether in-person or via telehealth, you need a prescriber licensed in Florida who conducts a real evaluation. This typically includes reviewing your weight history, metabolic labs (fasting glucose, HbA1c, lipid panel), BMI, and any contraindications. A prescription written after a two-minute chat with no labs is a red flag for prescriber non-compliance.

Step 2: Confirm the Pharmacy's Regulatory Status

Ask the pharmacy directly whether AOD-9604 appears on their current 503A bulk substances list, or whether they operate under an alternative legal basis. A reputable compounding pharmacy will provide a clear answer. If they cannot or will not explain their regulatory basis, choose a different pharmacy.

Step 3: Understand That Current Legal Supply Is Limited

Because the FDA placed AOD-9604 in Category 2 of the 503A review process, pharmacies legally able to compound it as a finished injectable are operating in a contested space. Some pharmacies that previously offered AOD-9604 have shifted to offering it as a research chemical only, labeled "not for human use," which shifts legal liability but does not make human use lawful.

Step 4: Consider Approved Alternatives

If your goal is body composition, FDA-approved options exist. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo. [5] Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). [6] These drugs have established safety data, are legally obtainable with a prescription, and have regulatory standing that AOD-9604 currently lacks.

What Physicians and Pharmacists Say

The Endocrine Society's position on peptide therapeutics emphasizes that compounds used for metabolic management should have established safety and efficacy data from adequately powered clinical trials before routine clinical use. As the Endocrine Society's clinical practice guidelines for obesity pharmacotherapy state: "Pharmacological therapy for obesity should be reserved for patients in whom lifestyle intervention alone has been insufficient and should use agents with demonstrated safety and efficacy in randomized controlled trials." AOD-9604's Phase III oral trial did not meet that bar.

A Florida-based compounding pharmacist, when asked about AOD-9604's current status, would be obligated to tell you that operating outside the FDA's 503A bulk list creates enforcement exposure, regardless of market demand.

The Research Chemical Loophole and Why It Is Not a Safe Harbor

Some online suppliers sell AOD-9604 labeled "for research use only" or "not for human use." This label does not create a legal loophole for patients or physicians.

The FDA has been explicit: labeling a substance "research use only" does not exempt it from the adulterated or misbranded drug provisions of the Federal Food, Drug, and Cosmetic Act if the substance is intended for human use. The FDA's guidance document on research chemicals and the FD&C Act clarifies that intended use determines regulatory status, not the label. A physician who recommends a "research chemical" supplier to a patient is recommending an unregulated product with no quality controls, no sterility assurance, and no verified peptide content.

Quality and Safety Considerations Independent of Legality

Even setting legality aside, the quality risk is real. Independent analyses of peptide products sold online have found that purity ranges from below 60% to above 99%, with no way for a consumer to distinguish between them. A 2022 analysis published in Drug Testing and Analysis found significant discrepancies in peptide content between labeled and actual concentrations in commercially obtained research peptides, with some samples containing unidentified impurities. Injectable products with substandard sterility create infection risks that are not theoretical. Subcutaneous abscess formation has been reported with self-administered peptide injections from unverified sources.

Summary of Key Legal Facts

| Factor | Current Status | |---|---| | FDA-approved drug | No | | DEA scheduled substance | No | | 503A bulk list | Category 2 (not approved) | | 503B compounding eligibility | Not eligible | | Florida state ban | None specific | | Prescription required | Yes | | Research use (IND) | Lawful pathway | | "Research chemical" labeling | Not a legal protection |